fluorometholone (fml) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Fluorometholone is a glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. Corticosteroids such as fluorometholone inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Corticosteroids are capable of producing a rise in intraocular pressure. In clinical studies of documented steroid-responders, fluorometholone demonstrated a significantly longer average time to produce a rise in intraocular pressure than dexamethasone phosphate.   NCATS

Chemistry

  • SMILES: C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]4(C)C=CC(=O)C=C14
  • InChIKey: FAOZLTXFLGPHNG-KNAQIMQKSA-N
  • Mol. Mass: 376.4617
  • ALogP: 2.92
  • ChEMBL Molecules:
    fluorometholone  
    fluorometholone acetate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$2.4499

United States

$8.7880 - $36.4700
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(1r,2s,8s,10s,11s,14r,15s,17s)-14-acetyl-1-fluoro-14,17-dihydroxy-2,8,15-trimethyltetracyclo[8.7.0.02,7.011,15]heptadeca-3,6-dien-5-one | 9-fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione | eflone | flarex | fluaton | flumetholon | flumetholone | fluormetholon | fluorometholon | fluorometholone | fluorométholone | fluorometholone acetate | fluorometholonum | fluorometolona | fluor-op | fml | fml forte | fml fte | fml-neo | nsc 33001 | oxylone | oxylone acetate | u-17323

Organizations (31)

Research & Development (23)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (9)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (17)

Approved Indications (1)


 

Inflammation (approved 1972)

Experimental Indications - Clinical Trial Phases 1-4 (17)


 

Corneal Diseases (Phase 4)

Corneal Opacity (Phase 2/Phase 3)

Dry Eye Syndromes (Phase 4)

Eye Diseases (Phase 4)

Eyelid Diseases (Phase 4)

Fibrosis (Phase 3)

Fuchs' Endothelial Dystrophy (Phase 4)

Glaucoma (Phase 3)

Inflammation (Phase 4)

Intraocular Pressure (Phase 4)

Lacrimal Apparatus Diseases (Phase 2)

Microvessels (Phase 4)

Rosacea (Phase 4)

Steroids (Phase 4)

Trabeculectomy (Phase 3)

Trachoma (Phase 4)

Trichiasis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial Organizations: 23

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue